Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P Rother

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Biotechniques|October 1, 1992
Increasing the specificity of oligo(dT)-primed PCRR P Rother
Sub-Cellular Biochemistry|July 7, 1999
alpha-Gal epitopes on viral glycoproteinsR P Rother, U Galili
Clinical and Experimental Immunology|March 1, 1991
La/SSB ribonucleoprotein levels increased in transformed cellsR P Rother, P S Thomas
Cell|July 26, 1996
The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatableR P Rother, S P Squinto
Lupus|July 3, 2004
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosusR P Rother, C F Mojcik, E W McCroskery
European Journal of Biochemistry|June 15, 1992
Purification, primary structure, bacterial expression and subcellular distribution of an oocyte-specific protein in XenopusR P Rother, M B Frank, P S Thomas
The Journal of Biological Chemistry|September 27, 1996
Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59R P Rother, J Zhao, Q Zhou, et al.
Haematologica|April 5, 2007
Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuriaA Hill, S J Richards, R P Rother, et al.
Human Gene Therapy|April 1, 1995
Protection of retroviral vector particles in human blood through complement inhibitionR P Rother, S P Squinto, J M Mason, et al.
Journal of Virology|May 30, 1998
Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped virusesR M Welsh, C L O'Donnell, D J Reed, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Biotechniques|October 1, 1992
Increasing the specificity of oligo(dT)-primed PCRR P Rother
Sub-Cellular Biochemistry|July 7, 1999
alpha-Gal epitopes on viral glycoproteinsR P Rother, U Galili
Clinical and Experimental Immunology|March 1, 1991
La/SSB ribonucleoprotein levels increased in transformed cellsR P Rother, P S Thomas
Cell|July 26, 1996
The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatableR P Rother, S P Squinto
Lupus|July 3, 2004
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosusR P Rother, C F Mojcik, E W McCroskery
European Journal of Biochemistry|June 15, 1992
Purification, primary structure, bacterial expression and subcellular distribution of an oocyte-specific protein in XenopusR P Rother, M B Frank, P S Thomas
The Journal of Biological Chemistry|September 27, 1996
Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59R P Rother, J Zhao, Q Zhou, et al.
Haematologica|April 5, 2007
Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuriaA Hill, S J Richards, R P Rother, et al.
Human Gene Therapy|April 1, 1995
Protection of retroviral vector particles in human blood through complement inhibitionR P Rother, S P Squinto, J M Mason, et al.
Journal of Virology|May 30, 1998
Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped virusesR M Welsh, C L O'Donnell, D J Reed, et al.
Pageof 3